Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
2 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
3 Alcoholic liver disease 💬
 3件: ADH1A, ADH1B, ADH1C 💬 D00707 💬 Fomepizole 1件: 301 💬
4 Alcoholic liver disease 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
5 AMPK signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
6 Apelin signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
7 Autophagy - animal 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
8 Bladder cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
9 Calcium signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
10 cGMP-PKG signaling pathway 💬
 1件: PDE5A 💬 D08514 💬 Sildenafil 17件:  6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬
11 Chagas disease 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
12 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
13 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
14 Circadian rhythm 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
15 Cytokine-cytokine receptor interaction 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
16 Drug metabolism - cytochrome P450 💬
 3件: ADH1A, ADH1B, ADH1C 💬 D00707 💬 Fomepizole 1件: 301 💬
17 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
18 Fatty acid degradation 💬
 3件: ADH1A, ADH1B, ADH1C 💬 D00707 💬 Fomepizole 1件: 301 💬
19 Fluid shear stress and atherosclerosis 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
20 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
21 Focal adhesion 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
22 FoxO signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
23 Glucagon signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
24 Glycolysis / Gluconeogenesis 💬
 3件: ADH1A, ADH1B, ADH1C 💬 D00707 💬 Fomepizole 1件: 301 💬
25 Herpes simplex virus 1 infection 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
26 HIF-1 signaling pathway 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
27 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
28 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
29 Human papillomavirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
30 Hypertrophic cardiomyopathy 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
31 Inflammatory bowel disease 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
32 Influenza A 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
33 Insulin resistance 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
34 Insulin signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
35 JAK-STAT signaling pathway 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
36 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: IFNGR1 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
37 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
38 Leishmaniasis 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
39 Longevity regulating pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
40 Longevity regulating pathway - multiple species 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
41 MAPK signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
42 Metabolic pathways 💬
 3件: ADH1A, ADH1B, ADH1C 💬 D00707 💬 Fomepizole 1件: 301 💬
43 Metabolic pathways 💬
 1件: PDE5A 💬 D08514 💬 Sildenafil 17件:  6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬
44 Metabolism of xenobiotics by cytochrome P450 💬
 3件: ADH1A, ADH1B, ADH1C 💬 D00707 💬 Fomepizole 1件: 301 💬
45 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
46 mTOR signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
47 Natural killer cell mediated cytotoxicity 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
48 Necroptosis 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
49 Non-alcoholic fatty liver disease 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
50 Osteoclast differentiation 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
51 Oxytocin signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
52 Pancreatic cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
53 Pathways in cancer 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
54 Pathways in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
55 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
56 PI3K-Akt signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
57 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
58 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
59 Purine metabolism 💬
 1件: PDE5A 💬 D08514 💬 Sildenafil 17件:  6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬
60 Pyruvate metabolism 💬
 3件: ADH1A, ADH1B, ADH1C 💬 D00707 💬 Fomepizole 1件: 301 💬
61 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
62 Ras signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
63 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
64 Renal cell carcinoma 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
65 Retinol metabolism 💬
 3件: ADH1A, ADH1B, ADH1C 💬 D00707 💬 Fomepizole 1件: 301 💬
66 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
67 Th1 and Th2 cell differentiation 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
68 Th17 cell differentiation 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
69 Thermogenesis 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
70 Tight junction 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
71 Toxoplasmosis 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
72 Tuberculosis 💬
 2件: IFNGR1, IFNGR2 💬 D00747 💬 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326 💬
73 Tyrosine metabolism 💬
 3件: ADH1A, ADH1B, ADH1C 💬 D00707 💬 Fomepizole 1件: 301 💬
74 VEGF signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬

先頭へ